However, through analyzing the survival of patients with tumor-bearing PTEN mutations, we found that the outcome of patients with stop-gained mutations was poorer than those with phosphatase-inactive mutations (Fig. 1b and supplementary Fig. 1a). The gene discussed is PTEN; the disease is neoplasm.